Welcome to our dedicated page for Passage Bio news (Ticker: PASG), a resource for investors and traders seeking the latest updates and insights on Passage Bio stock.
Passage Bio, Inc. (NASDAQ: PASG) is a clinical stage genetic medicines company whose news flow centers on the development of its lead gene therapy candidate, PBFT02, for neurodegenerative diseases. Company updates frequently highlight progress in the Phase 1/2 upliFT-D trial in frontotemporal dementia with GRN or C9orf72 mutations, including cohort enrollment, dosing milestones, and interim biomarker and safety data.
Investors following PASG news can expect regular announcements of quarterly and annual financial results, where Passage Bio reports research and development spending, general and administrative expenses, net loss, and cash, cash equivalents, and marketable securities, along with commentary on expected cash runway. These releases often include recent business highlights related to PBFT02, such as data readouts on cerebrospinal fluid progranulin levels, plasma neurofilament light chain trends, and protocol amendments intended to refine the benefit–risk profile of the program.
News items also cover regulatory and manufacturing developments, including interactions with the U.S. Food and Drug Administration on analytical comparability for a high-productivity, suspension-based PBFT02 manufacturing process, and plans to seek feedback on potential registrational trial designs. In addition, Passage Bio regularly announces participation in healthcare, genetic medicines, and biopharma investor conferences, where management presents corporate overviews and program updates.
This page aggregates these disclosures, offering a centralized view of Passage Bio’s clinical, regulatory, financial, and corporate communications. Readers interested in PASG can use this news feed to track the evolution of the PBFT02 program, changes in trial design, manufacturing strategy, and key financial and listing-related events such as the company’s reverse stock split and subsequent confirmation of compliance with Nasdaq listing requirements.
Passage Bio, a clinical-stage genetic medicines company (Nasdaq: PASG), announces the opening of its Tachi Yamada Scholarship program for rising juniors majoring in life sciences at Pennsylvania colleges. The $10,000 scholarship, awarded annually, aims to support students committed to careers in life sciences. Applications are due by April 1, 2023, for the initial award in fall 2023. The scholarship honors the legacy of Dr. Tachi Yamada, co-founder and former chairman of the board, who championed mentorship in the field. The selected scholar will also receive mentorship opportunities over two years for professional development.
Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company, announced CEO William Chou will participate in a corporate panel at the Cowen 43rd Annual Health Care Conference on March 7, 2023, at 10:30 a.m. ET in Boston, MA. This event will focus on therapies for central nervous system disorders. A live webcast will be accessible on Passage Bio's website, with a replay available for 30 days post-event. The company is advancing treatments for CNS diseases, including GM1 gangliosidosis and frontotemporal dementia, leveraging a collaboration with the University of Pennsylvania's Gene Therapy Program.
Passage Bio (NASDAQ: PASG) announced a conference call on March 6, 2023, at 8:30 a.m. ET to discuss its Q4 and full-year 2022 financial results and recent business developments. The company focuses on developing gene therapies for central nervous system disorders, including GM1 gangliosidosis and frontotemporal dementia. Through a collaboration with the University of Pennsylvania’s Gene Therapy Program, Passage Bio enhances its access to gene therapy candidates, leveraging its clinical and regulatory expertise. Investors can access the webcast on the company's website post-event.
Passage Bio, Inc. (Nasdaq: PASG) announced new data from its Phase 1/2 study of PBGM01, a gene therapy for GM1 gangliosidosis, presented at the 19th Annual WORLD Symposium. The updated interim results indicate that PBGM01 administration led to stabilization of MRI severity scores in all treated patients over a follow-up of 6 to 12 months, suggesting positive biological effects. Additionally, decreases in urine levels of β-Gal substrate Dp5 were observed, indicating increased β-Gal activity. The therapy shows a favorable safety profile with no serious adverse events reported, bolstering confidence in PBGM01 as a potential treatment option for this rare disease.
Passage Bio has announced its participation in the 19th Annual WORLD Symposium™ from February 22-26, 2023, in Orlando, Florida, where it will share updated interim data from the Phase 1/2 Imagine-1 study of PBGM01 for GM1 gangliosidosis. The presentations by Jeanine Jarnes, Pharm D., from the University of Minnesota, are scheduled for February 24, 2023, with the oral presentation at 2:00 p.m. ET and a poster session at 3:00 p.m. ET. PBGM01, a gene therapy using AAV technology, targets GM1 gangliosidosis, a rare lysosomal storage disorder affecting the CNS. The FDA has granted it several designations, including Fast Track and Orphan Drug.
On January 20, 2023, Passage Bio (Nasdaq: PASG) announced the granting of stock options to a new employee as an inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The options, totaling 7,600 shares, have an exercise price of $1.67 per share, equal to its closing price on the grant date, January 17, 2023. These stock options will vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments thereafter. Passage Bio focuses on developing therapies for CNS disorders with ongoing clinical programs targeting conditions like GM1 gangliosidosis and frontotemporal dementia.
Passage Bio (NASDAQ: PASG) provided interim safety and biomarker results from its Phase 1/2 Imagine-1 clinical study of PBGM01 in pediatric patients with GM1 Gangliosidosis. The low and high doses of PBGM01 were well tolerated, with no serious adverse events reported. The therapy showed promising results, including dose-dependent increases in CSF β-Gal activity and decreases in GM1 gangliosides. Initial results from the completed dosing of Cohort 4 are expected by mid-2023, highlighting the ongoing development of this potential treatment.
Passage Bio, Inc. (NASDAQ: PASG) has provided updates on its clinical trials and financial results for Q3 2022. The company dosed the first patient in the final cohort of the Imagine-1 trial for GM1 gangliosidosis and the upliFT-D trial for frontotemporal dementia. While cash reserves were $213.8 million, R&D expenses decreased to $15.4 million, and G&A expenses dropped to $10.7 million. Despite a net loss of $26.7 million, the cash runway is extended into 2025. The company plans to present safety data in December 2022 and refocus on key trials.
Passage Bio (NASDAQ: PASG), a clinical-stage genetic medicines company, announced CEO William Chou will participate in a fireside chat at the Guggenheim 4th Annual Immunology & Neurology Day on November 15, 2022, at 10:10 a.m. ET in New York City. A live webcast will be accessible on their website, and a replay will be available for 30 days post-event. The company is focused on developing therapies for CNS disorders, with ongoing programs in GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia, enhancing treatment access through its collaboration with the University of Pennsylvania.
Passage Bio (NASDAQ: PASG) will host a conference call on November 10, 2022, at 8:30 a.m. ET to discuss its third quarter 2022 financial results and recent business updates. The company focuses on genetic therapies for CNS disorders and is advancing three clinical programs targeting GM1 gangliosidosis, Krabbe disease, and frontotemporal dementia. Passage Bio collaborates with the University of Pennsylvania’s Gene Therapy Program for its research and development efforts. Archived webcasts will be available post-event for 30 days.